Raise closed, search for fresh raises on Seedstage

Lone Tree, CO

Raising funds to expand lab operations and enhance AI-driven data analytics for autologous cell therapies.

• Mission: Advancing regenerative medicine through personalized autologous cell therapies, using patient-specific cells to improve treatment outcomes.  
• Innovation: Combines precision data analytics with cutting-edge cell therapy technology to optimize and customize regenerative treatments.  
• Market Opportunity: Positioned to lead in the rapidly expanding $62 billion global cell therapy market, addressing rising demand for tailored, effective treatments.  
• Sustainability Impact: Focuses on improving patient outcomes with therapies that utilize the body’s own cells, reducing the need for donor cells and minimizing risks.  
• Strategic Positioning: Expanding operations with new labs in key U.S. and European markets, enhancing production capacity and AI-driven advancements.  
• Leadership: Led by Dr. David Karli, a Harvard-trained physician with deep expertise in regenerative medicine, guiding the company’s growth in the evolving healthcare landscape.  

Greyledge Technologies is raising funds to further develop its autologous cell therapies, utilizing data-driven analytics to enhance the consistency and efficacy of regenerative medicine treatments. The company specializes in processing blood, bone marrow, and adipose (fat) cells, offering customized solutions to healthcare providers. By combining precision data analytics with cutting-edge cell therapy technology, Greyledge aims to improve patient outcomes and revolutionize the growing cell therapy market. The funds raised will be used to expand lab operations, support AI-driven advancements, and optimize cell processing at their facilities across the U.S. and Europe.

The global cell therapy market is projected to reach $62 billion by 2030, creating significant opportunities for Greyledge’s tailored approach to autologous therapies. With new labs recently established in Miami, Dallas, Columbus, and Croatia, the company is poised for growth. Their data cloud system integrates seamlessly into physician workflows, providing real-time insights that support informed decision-making in patient care. By enhancing manufacturing quality and ensuring treatment consistency, Greyledge Technologies is strategically positioned to lead in the evolving regenerative medicine landscape.

Company Info

Greyledge Technologies is a biotechnology company specializing in autologous cell therapies and AI-driven data analytics to optimize patient treatment outcomes.

Greyledge Technologies is a biotechnology company focused on developing autologous cell therapies, which use a patient’s own cells for treatment. The company operates 11 processing labs across the U.S. and Europe, with new facilities in Miami, Dallas, Columbus, and Zagreb. Their research focuses on blood, bone marrow, and adipose cell therapies, supported by AI-driven data analysis and medical device automation. Greyledge’s precision dosing technology allows physicians to customize cell therapies to match individual patient needs and conditions, optimizing treatment outcomes.

The company’s data analytics platform enhances product performance by providing real-time insights to healthcare providers, facilitating data-driven decision-making. Greyledge aims to improve the consistency, predictability, and effectiveness of autologous therapies, which are increasingly in demand within the expanding $62 billion global cell therapy market. With a leadership team led by Dr. David Karli, a Harvard-trained physician with extensive experience in regenerative medicine, Greyledge is positioning itself as a key player in the regenerative medicine sector, utilizing data analytics to drive the evolution of cell therapies.